The UK-based company has developed its proprietary Bi-Cygni technology, which utilises Antibody Drug Conjugates to treat various cancers, including Acute Myeloid Leukaemia. BiVictriX is generating a new class of next-generation anti-cancer therapeutics with superior selectivity towards cancer, overcoming the debilitating and sometimes fatal toxic side-effects associated with existing antibody-based approaches. The Bi-Cygni approach links the company's in-house panel of cancer-restricted twin antigen fingerprints to generate the next generation of bispecific ADC therapeutics with enhanced therapeutic index, across a broad range of malignant indications. The company's initial focus is on the generation of Bi-Cygni ADCs, with plans to expand the technology to other therapeutic modalities such as cell engagers and CAR-T.